期刊文献+

uPA、PAI-1的表达和MVD计数与浸润性乳腺癌侵袭性的关系 被引量:3

Relationship Between Expression of uPA,PAI-1 and Microvessel Density and Invasiveness of Primary Invasive Breast Cancer
原文传递
导出
摘要 目的:探讨尿激酶型纤溶酶原激活剂(uPA)、纤溶酶原激活物抑制剂(PAI-1)的表达和血管形成与浸润性乳腺癌侵袭性的关系。方法:应用免疫组化SP法检测80例浸润性乳腺癌、20例良性乳腺肿瘤组织中uPA、PAI-1的表达情况并进行微血管计数。结果:uPA和PAI-1在浸润性乳腺癌组的阳性表达显著高于良性肿瘤组,且其高表达率与乳腺癌的临床病理参数密切相关(P<0.05);微血管计数在乳腺癌组和良性肿瘤组分别为30.87±7.64、20.28±8.72,两组比较有显著性差异(P<0.01)。uPA与PAI-1在浸润性乳腺癌中的表达呈正相关(P<0.05)。结论:uPA、PAI-1的高表达与浸润性乳腺癌的浸润、转移相关,uPA、PAI-1的高表达和MVD计数可作为评价浸润性乳腺癌侵袭性、评估预后和确定治疗方案的生物学指标。 Objective:To detect the expression of uPA(urokinase plasminogen activator)、PAI-1(plasminogen activator inhibitor type 1) and angiogenesis in breast cancer and their relationship with the invasiveness of breast cancer.Methods:Eighty surgically resected breast cancer samples and twenty breast benign tumor samples were selected.S-P immunostaining technique was used to detect the expression of uPA、PAI-1and MVD in all of the tissues.Results:The positive expression rates of uPA、PAI-1 in breast cancer was significantly higher than that in the breast benign tumors,and their high expression rates were related with the clinical pathology parameters of the breast cancer(P0.05).MVD were respectively 30.87±7.64,20.28±8.72 in breast cancer and breast benign tumor group.There was significantly difference between the two groups(P0.01).There were positive correlations between the level of uPA and PAI-1 in breast cancer(P0.05).Conclusion:The expression of uPA and PAI-1 correlated with the invasiveness and metastasis of breast cancer,and they could be used as biological indicators that evaluate the invasiveness and metastasis,estimate prognosis and determine treatment of primary invasive breast cancer.
出处 《现代生物医学进展》 CAS 2011年第12期2307-2309,共3页 Progress in Modern Biomedicine
关键词 尿激酶型纤溶酶原激活因子 尿激酶型纤溶酶原激活物抑制因子 乳腺癌 侵袭性 免疫组化 Urokinase plasminogen activator(uPA) Plasminogen activator inhibitor(PAI-1) Breast cancer Invasiveness Immunohistochemistry
  • 相关文献

参考文献16

  • 1Weidner N,Folkman J,Pozza F,et al.Tumorangiogenesis: a new significantand independent prognostic indicatorin early-stage breast carcinoma[J].J Natl cancer Inst, 1992,84:1875-1887.
  • 2金晓明,李雅馨,李金荣,李宁毅,贾暮云.基质降解酶u-PA、PAI-1与人口腔鳞状细胞癌细胞侵袭转移的相关性研究[J].现代口腔医学杂志,2003,17(5):398-400. 被引量:1
  • 3Macchione E, Epifano O, Stefanini M, et al. Urokinase redistribution from the secreted to cell-bound fraction in granulosa cells of rat preovulatory follicles[J]. Biol Reprod,2000, 62 (4) : 895-897.
  • 4Han, B., Nakamura,M.,Mori, I., Nakamura, Y. and Kakudo, K. Urokinase-type plasminogen activator system and breast cancer [J]. Oncol, 2005,14:105-112.
  • 5Duffy MJ. The urokinase plasminogen activator system: Role in malignancy[J]. Curr Pharm Des, 2004,10:39-49.
  • 6Sandstrom M , JohanssonM , Sandstrom J, et al. Expression of the proteolytic factors, tPA and uPA, PAl-1 and VEGF during malignant glioma progression [J]. Int J Dev Neurosci, 1999, 17 (5) : 473-481.
  • 7B.Markl,Prof.I.Renk,D.V.Oruzio,et al. Tumour Budding, uPA and PAI-1 Are Associated With Aggressive Behaviour in Colon Cancer [J].Journal of Surgical Oncology, 2010,102:235-241.
  • 8肖继平,於席芳,徐翠琼,张莉,何赋容,王梅林,张广德,夏文华.腋淋巴结阴性乳腺癌uPA表达的临床意义[J].中华肿瘤杂志,2004,26(3):188-188. 被引量:19
  • 9Lademann UA, Romer MU. Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAI-1).[J] Thromb Haemost, 2008,100:1041-1046.
  • 10Fran-oise Descotes,Benjamin Riche,Simone Saez, et al.Plasminogen Activator Inhibitor Type 1 is the Most Significant of the Usual Tissue Prognostic Factors in Node-Negative Breast Ductal Adenocarcinoma Independent of Urokinase-Type Plasminogen Activator [J].Clinical Breast Cancer, 2008,8(2): 168-177.

二级参考文献13

  • 1刘刚 李金荣.口腔鳞癌转移癌细胞系体外转移特性的体外研究[J].中华口腔医学杂志,1999,34(3):167-167.
  • 2Quax PHA, Mujen GNP, Verhoff EJDW. Metastasis behavior of human mdanoma lines in nude mice correlates with urokinasetype plasminogen activator, its type - 1 inhibitor and urokinasemediated matrix degradation. Cell Biology, 1991,115 : 191.
  • 3Grebenschikov N, Geurts - Moespot A, De witte H, et al. A sensitive and robust assay for urokinase and tissue- type plasminogen activators(u- PA and t - PA)and their inhibitor typeI (PAl - 1)in breast tumor cytosols. Int J Biol Markers, 1997,12:6- 14.
  • 4Sumiyoshi K, Baba S, Sakaguchi, et al. Increase in levels of plasminogen activator and type 1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis. Thromb Res, 1991,63 : 159.
  • 5Oka Takeshi, Teruyoshi Ishida, Toyohiko Nishino, et al.Immunohistochemical evidence of urokinase - type plasminogen activator in primary and metastatic of pulmonary adenocarcinoma Cancer Res, 1991,51:3522.
  • 6Choong PF, Ferno M, Akerman M, et al. Urokinase - plasminogen activator levels and progress in soft - tissue sarcomas. Cancer,1996,69 : 268.
  • 7Yonemura Y,Nojima N, Kaji M, et al. E- cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma.Cancer, 1995,76 : 941.
  • 8Hildenbrand R, Dilger I, Horlin A, et al. Urokinase plawninogen activator induces angiogenesis and tumor vessel invasion in breast cancer. Pathol Res Pract, 1995,191:403.
  • 9Hofmann R, Lehmer A, Buresch M, et al. Clincial relevance of urokinase activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer, 1996,78: 487.
  • 10Yasude T, Sakata Y, Kitamura K, et al. Loclization of plasminogen activator and their inhibitors in squamous cell carcinomas of the head and neck. Head Neck, 1997,19:611 - 616.

共引文献18

同被引文献48

  • 1孟丽,山峰,孙波,王蓁.子宫内膜癌患者血清uPA和PAI-1的含量变化及临床意义[J].现代妇产科进展,2007,16(8):573-576. 被引量:6
  • 2Herz J,Clouthier de,Hummer RE. LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embroimplantation[J].Cell,1992,(03):411-421.doi:10.1016/0092-8674(92)90511-A.
  • 3Oison d,Pollanen J,Hoyer-Hansen G. Internalization of the urokinase:plasminogen activitor inhibitor type-1 complex is mediated by the urokinase receptor[J].Journal of Biological Chemistry,1992,(13):9129-9133.
  • 4Baricos WH,Cortez SL,EI-Dharss. ECM degradation by cultured human mesangial cell is mediated by a PA/plasmin/ MMP-2 cascade[J].Kidney International,1995,(04):1039-1047.doi:10.1038/ki.1995.150.
  • 5Schmierer B,Hill CS. TGFbeta-SMAD signal transduction:molecular specificity and functional flexibility[J].Nature Reviews Molecular Cell Biology,2007,(12):970-982.doi:10.1038/nrm2297.
  • 6Kunz C,Pebler S,Otte J,der Ahe Dv. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor P53[J].Nucleic Acids Research,1995,(18):3710-3717.doi:10.1093/nar/23.18.3710.
  • 7Sprengers EB,Kluft C. Plasminogen Activator Inhibitors[J].Blood,1987,(02):381-387.
  • 8BorgfeldtC,Casslen B,Liu CL. High tissue content of urokinase plasminogen activator (uPA) is associated with high stromal expression of uPA mRNA in poorly differentiated serous ovarian carcinoma[J].International Journal of Cancer,1998,(06):588-595.doi:10.1002/(SICI)1097-0215(19981218)79:6<588::AID-IJC6>3.0.CO;2-W.
  • 9Schmalfeld B,KuhnW,ReuningL. Primary tumorandmetastasis in ovarian cancer differ in their contentofurokinase-type plasminogen activator,its receptor,and inhibitors types 1 and 2[J].Cancer Research,1995,(18):3958-3963.
  • 10Sakakibara T,Hibi K,Kodera Y. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of esophageal squamous cell carcinoma[J].Clinical Cancer Research,2004,(04):1375-1378.doi:10.1158/1078-0432.CCR-03-0196.

引证文献3

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部